Ezt az oldalt automatikusan lefordították, és a fordítás pontossága nem garantált. Kérjük, olvassa el a angol verzió forrásszöveghez.

Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older

2018. szeptember 20. frissítette: GlaxoSmithKline

Open-label Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 50 Years or Older

The purpose of this study is to assess the safety and immunogenicity of the GSK Biologicals' HZ vaccine 1437173A administered on either a 0,2-; 0,6- or 0,12-month schedule in adults aged 50 years or above, as the immunogenicity of the HZ vaccine administered at intervals longer than two months is not known.

A tanulmány áttekintése

Állapot

Befejezve

Körülmények

Részletes leírás

Subjects in each group will be stratified by age with a minimum of 35 subjects in each stratum (50-59 years of age (YOA) stratum, 60-69 YOA stratum and ≥ 70 YOA stratum).

Tanulmány típusa

Beavatkozó

Beiratkozás (Tényleges)

354

Fázis

  • 3. fázis

Kapcsolatok és helyek

Ez a rész a vizsgálatot végzők elérhetőségeit, valamint a vizsgálat lefolytatásának helyére vonatkozó információkat tartalmazza.

Tanulmányi helyek

    • California
      • Spring Valley, California, Egyesült Államok, 91978
        • GSK Investigational Site
    • Kansas
      • Wichita, Kansas, Egyesült Államok, 67207
        • GSK Investigational Site
    • Pennsylvania
      • Uniontown, Pennsylvania, Egyesült Államok, 15401
        • GSK Investigational Site
      • Tartu, Észtország, 50106
        • GSK Investigational Site

Részvételi kritériumok

A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.

Jogosultsági kritériumok

Tanulmányozható életkorok

50 év és régebbi (Felnőtt, Idősebb felnőtt)

Egészséges önkénteseket fogad

Igen

Tanulmányozható nemek

Összes

Leírás

Inclusion Criteria:

  • Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • A male or female aged 50 years or older at the time of the first vaccination.
  • Written informed consent obtained from the subject.
  • Female subjects of non-childbearing potential may be enrolled in the study.

    • Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause.
  • Female subjects of childbearing potential may be enrolled in the study, if the subject:

    • has practiced adequate contraception for 30 days prior to vaccination, and
    • has a negative pregnancy test on the day of vaccination, and
    • has agreed to continue adequate contraception during the entire treatment period and for two months after completion of the vaccination series.

Exclusion Criteria:

  • Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. For corticosteroids, a prednisone dose of < 20 mg/day, or equivalent, is allowed. Inhaled, topical and intra-articular corticosteroids are allowed.
  • Administration or planned administration of a live vaccine in the period starting 30 days before and ending 30 days after either dose of study vaccine.
  • Administration or planned administration of a non-replicating vaccine within eight days prior to or within 14 days after either dose of study vaccine.
  • Administration of long-acting immune-modifying drugs (e.g. infliximab) within six months prior to the first vaccine dose or expected administration at any time during the study period.
  • Previous vaccination against varicella or HZ (either registered product or participation in a previous vaccine study).
  • Planned administration during the study of an HZ or varicella vaccine (including an investigational or non-registered vaccine) other than the study vaccine.
  • History of HZ.
  • History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine(s).
  • Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease (e.g. malignancy, human immunodeficiency virus [HIV] infection) or immunosuppressive/cytotoxic therapy (e.g. medications used during cancer chemotherapy, organ transplantation or to treat autoimmune disorders).
  • Acute disease and/or fever at the time of enrolment.

    • Fever is defined as temperature ≥ 37.5°C (99.5°F) for oral, axillary or tympanic route, or ≥ 38.0°C (100.4°F) for rectal route. The preferred route for recording temperature in this study will be oral.
    • Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may be enrolled at the discretion of the investigator.
  • Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.
  • Significant underlying illness that, in the opinion of the investigator, would be expected to prevent completion of the study.
  • Any other condition that, in the opinion of the investigator, might interfere with the evaluations required by the study.
  • Pregnant or lactating female.
  • Female planning to become pregnant during the entire treatment period and for two months after completion of the vaccination series, or planning to discontinue contraceptive precautions (if of childbearing potential).

Tanulási terv

Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.

Hogyan készül a tanulmány?

Tervezési részletek

  • Elsődleges cél: Megelőzés
  • Kiosztás: Véletlenszerűsített
  • Beavatkozó modell: Párhuzamos hozzárendelés
  • Maszkolás: Nincs (Open Label)

Fegyverek és beavatkozások

Résztvevő csoport / kar
Beavatkozás / kezelés
Kísérleti: HZ/su-0,2 Group
Subjects will receive HZ/su vaccine on a 0,2-month schedule.
2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
Kísérleti: HZ/su-0,6 Group
Subjects will receive HZ/su vaccine on a 0,6-month schedule.
2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
Kísérleti: HZ/su-0,12 Group
Subjects will receive HZ/su vaccine on a 0,12-month schedule.
2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.

Mit mér a tanulmány?

Elsődleges eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Number of Subjects With Vaccine Response to Anti-glycoprotein E (Anti-gE) Antibodies as Determined by the Enzyme-linked Immunosorbent Assay (ELISA).
Időkeret: At one month (M1) after Dose 2

Vaccine response was defined as: for initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x97 mIU/mL); for initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration.

The objective required a comparison of VRR between 0,6-months and 0,12-months schedules.

At one month (M1) after Dose 2
Concentrations of Antibodies Against Anti-gE as Determined by ELISA.
Időkeret: At one month (M1) after Dose 2
At one month (M1) after Dose 2

Másodlagos eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Concentrations of Antibodies Against Anti-gE as Determined by ELISA.
Időkeret: Prior (PRE) to vaccination and twelve (M12) post Dose 2
Prior (PRE) to vaccination and twelve (M12) post Dose 2
Number of Subjects With Solicited Local Symptoms.
Időkeret: During the 7 day period (Days 0-6) following each dose (D)
Solicited local symptoms assessed include pain, redness and swelling. "Grade 3 pain" was defined as crying when limb was moved/spontaneously painful. "Grade 3 swelling/redness" was defined as swelling/redness larger than (>) 100 millimeters (mm). "Any" is defined as incidence of the specified symptom regardless of intensity.
During the 7 day period (Days 0-6) following each dose (D)
Number of Subjects With Solicited General Symptoms.
Időkeret: During the 7 day period (Days 0-6) following each dose (D)
Assessed solicited general symptoms were Fatigue, Gastrointestinal (meaning nausea, vomiting, diarrhoea and/or abdominal pain), Headache, Myalgia, Shivering and Temperature (temperature higher than [≥] 37.5 degrees Celsius [°C]). "Any" = occurrence of the specified solicited general symptom, regardless of intensity or relationship to vaccination. "Related" = occurrence of the specified symptom assessed by the investigators as causally related to vaccination. "Grade 3 Fatigue" = fatigue that prevented normal activity. "Grade 3 Gastrointestinal" = gastrointestinal that prevented normal every day activities. "Grade 3 Headache" = headache that prevented normal activity. "Grade 3 Myalgia" = myalgia that prevented normal activity. "Grade 3 Shivering" = shivering that prevented normal activity. "Grade 3 Temperature" = temperature higher than (>) 39.0°C.
During the 7 day period (Days 0-6) following each dose (D)
Number of Subjects With Unsolicited Adverse Events (AEs).
Időkeret: During the 30 Days (Day 0-29) following vaccination
An adverse event (AE) is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
During the 30 Days (Day 0-29) following vaccination
Number of Subjects With Serious Adverse Events (SAEs).
Időkeret: From first vaccination up to one month (30 Days) post last vaccination
SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity.
From first vaccination up to one month (30 Days) post last vaccination
Number of Subjects With SAE(s).
Időkeret: Starting from 30 Days post last vaccine administration up to study end at Month 24
SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity.
Starting from 30 Days post last vaccine administration up to study end at Month 24
Number of Days With Solicited Local Symptoms.
Időkeret: During the 7 Days (Day 0-6) following vaccination
Each dose was abbreviated as follows: D1 = Dose 1, D2 = Dose 2.
During the 7 Days (Day 0-6) following vaccination
Number of Days With Solicited General Symptoms.
Időkeret: During the 7 Days (Day 0-6) following vaccination
Each dose was abbreviated as follows: D1 = Dose 1, D2 = Dose 2.
During the 7 Days (Day 0-6) following vaccination
Number of Subjects With Potential Immune-mediated Diseases (pIMDs).
Időkeret: From Dose 1 up to one month (30 days) following the last vaccine dose administration (Dose 2)
pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
From Dose 1 up to one month (30 days) following the last vaccine dose administration (Dose 2)
Number of Subjects With pIMDs.
Időkeret: From one month (30 Days) following the last vaccine administration up to study end at Month 24
pIMDs are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
From one month (30 Days) following the last vaccine administration up to study end at Month 24

Együttműködők és nyomozók

Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.

Szponzor

Publikációk és hasznos linkek

A vizsgálattal kapcsolatos információk beviteléért felelős személy önkéntesen bocsátja rendelkezésre ezeket a kiadványokat. Ezek bármiről szólhatnak, ami a tanulmányhoz kapcsolódik.

Tanulmányi rekorddátumok

Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.

Tanulmány főbb dátumok

Tanulmány kezdete

2013. március 12.

Elsődleges befejezés (Tényleges)

2014. május 22.

A tanulmány befejezése (Tényleges)

2015. április 8.

Tanulmányi regisztráció dátumai

Először benyújtva

2012. december 13.

Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak

2012. december 13.

Első közzététel (Becslés)

2012. december 17.

Tanulmányi rekordok frissítései

Utolsó frissítés közzétéve (Tényleges)

2018. október 18.

Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak

2018. szeptember 20.

Utolsó ellenőrzés

2018. június 1.

Több információ

A tanulmányhoz kapcsolódó kifejezések

Terv az egyéni résztvevői adatokhoz (IPD)

Tervezi megosztani az egyéni résztvevői adatokat (IPD)?

IGEN

IPD terv leírása

IPD for this study will be made available via the Clinical Study Data Request site.

IPD megosztási időkeret

IPD is available via the Clinical Study Data Request site (click on the link provided below)

IPD-megosztási hozzáférési feltételek

Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Az IPD megosztását támogató információ típusa

  • STUDY_PROTOCOL
  • NEDV
  • ICF
  • CSR

Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .

Iratkozz fel